These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34890632)

  • 1. Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy.
    Gupta S; Jiskoot W; Schöneich C; Rathore AS
    J Pharm Sci; 2022 Apr; 111(4):903-918. PubMed ID: 34890632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.
    Alam ME; Slaney TR; Wu L; Das TK; Kar S; Barnett GV; Leone A; Tessier PM
    J Pharm Sci; 2020 Jan; 109(1):656-669. PubMed ID: 31678251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Stress Stability Studies Reveal the Prominent Stability of the Liquid-Formulated Biotherapeutic Asymmetric Monovalent Bispecific IgG1 Monoclonal Antibody Format.
    Sankaran PK; Poskute R; Dewis L; Watanabe Y; Wong V; Fernandez LP; Shannon R; Wong L; Shrubsall R; Carman L; Holt A; Lepore G; Mishra R; Sewell L; Gothard M; Cheeks M; Lindo V
    J Pharm Sci; 2024 Aug; 113(8):2101-2113. PubMed ID: 38705464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner.
    Alam ME; Barnett GV; Slaney TR; Starr CG; Das TK; Tessier PM
    Mol Pharm; 2019 May; 16(5):1939-1949. PubMed ID: 30916563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies.
    Timm V; Gruber P; Wasiliu M; Lindhofer H; Chelius D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Mar; 878(9-10):777-84. PubMed ID: 20153988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling.
    Zhang A; Hu P; MacGregor P; Xue Y; Fan H; Suchecki P; Olszewski L; Liu A
    Anal Chem; 2014 Apr; 86(7):3468-75. PubMed ID: 24597564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization.
    An Y; Zhang Y; Mueller HM; Shameem M; Chen X
    MAbs; 2014; 6(4):879-93. PubMed ID: 24927271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody disulfide bond reduction and recovery during biopharmaceutical process development-A review.
    Ren T; Tan Z; Ehamparanathan V; Lewandowski A; Ghose S; Li ZJ
    Biotechnol Bioeng; 2021 Aug; 118(8):2829-2844. PubMed ID: 33844277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using bispecific antibodies in forced degradation studies to analyze the structure-function relationships of symmetrically and asymmetrically modified antibodies.
    Evans AR; Capaldi MT; Goparaju G; Colter D; Shi FF; Aubert S; Li LC; Mo J; Lewis MJ; Hu P; Alfonso P; Mehndiratta P
    MAbs; 2019; 11(6):1101-1112. PubMed ID: 31161859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.
    Wang Y; Li X; Liu YH; Richardson D; Li H; Shameem M; Yang X
    MAbs; 2016; 8(8):1477-1486. PubMed ID: 27598507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of post-translational modifications in therapeutic antibodies.
    Vatsa S
    MAbs; 2022; 14(1):2023938. PubMed ID: 35040751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies.
    Dashivets T; Stracke J; Dengl S; Knaupp A; Pollmann J; Buchner J; Schlothauer T
    MAbs; 2016; 8(8):1525-1535. PubMed ID: 27612038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualification of a Quantitative Method for Monitoring Aspartate Isomerization of a Monoclonal Antibody by Focused Peptide Mapping.
    Cao M; Mo WD; Shannon A; Wei Z; Washabaugh M; Cash P
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):490-507. PubMed ID: 27091886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability testing in monoclonal antibodies.
    Kaur H
    Crit Rev Biotechnol; 2021 Aug; 41(5):692-714. PubMed ID: 33596751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of outcomes of amino acid modifications using a combinatorial approach to reveal physical and structural perturbations: A case study using trastuzumab biosimilar.
    Kamble R; Puranik A; Narvekar A; Dandekar P; Jain R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Oct; 1209():123430. PubMed ID: 35988497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization and kinetic modeling of interchain disulfide bond reoxidation of monoclonal antibodies in bioprocesses.
    Tang P; Tan Z; Ehamparanathan V; Ren T; Hoffman L; Du C; Song Y; Tao L; Lewandowski A; Ghose S; Li ZJ; Liu S
    MAbs; 2020; 12(1):1829336. PubMed ID: 33031716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic Modeling of Methionine Oxidation in Monoclonal Antibodies from Hydrogen Peroxide Spiking Studies.
    Hui A; Lam XM; Kuehl C; Grauschopf U; Wang YJ
    PDA J Pharm Sci Technol; 2015; 69(4):511-25. PubMed ID: 26242787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of monoclonal antibody variants involved in aggregate formation - Part 2: Hydrophobicity variants.
    Meyer RM; Berger L; Nerkamp J; Scheler S; Nehring S; Friess W
    Eur J Pharm Biopharm; 2021 Mar; 160():134-142. PubMed ID: 33524536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing antibody stability: Effects of stressors on Ipilimumab from the commercial formulation to diluted solutions.
    Fongaro B; Cian V; Gabaldo F; De Paoli G; Miolo G; Polverino de Laureto P
    Eur J Pharm Biopharm; 2022 Jul; 176():54-74. PubMed ID: 35595030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical and physical instabilities in manufacturing and storage of therapeutic proteins.
    Krause ME; Sahin E
    Curr Opin Biotechnol; 2019 Dec; 60():159-167. PubMed ID: 30861476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.